Condition: Thyroid Neoplasm
rs121913364 in
BRAF gene and
Thyroid Neoplasm
PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
rs104894230 in
HRAS;LRRC56 gene and
Thyroid Neoplasm
PMID 23406027 2013 Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.
PMID 17384584 2007 Hyperactive Ras in developmental disorders and cancer.
PMID 19773371 2009 Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma.
PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
PMID 19255327 2009 Phase II trial of sorafenib in metastatic thyroid cancer.
rs1057519725 in
KRAS gene and
Thyroid Neoplasm
PMID 19773371 2009 Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma.
PMID 19255327 2009 Phase II trial of sorafenib in metastatic thyroid cancer.
PMID 23406027 2013 Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.
PMID 17384584 2007 Hyperactive Ras in developmental disorders and cancer.
PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
rs104894228 in
LRRC56;HRAS gene and
Thyroid Neoplasm
PMID 19773371 2009 Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma.
PMID 23406027 2013 Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.
PMID 25157968 2014 Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
PMID 17384584 2007 Hyperactive Ras in developmental disorders and cancer.
PMID 19255327 2009 Phase II trial of sorafenib in metastatic thyroid cancer.
PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
rs11554290 in
NRAS gene and
Thyroid Neoplasm
PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
rs1057519936 in
PIK3CA gene and
Thyroid Neoplasm
PMID 26619011 2016 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
rs74799832 in
RET gene and
Thyroid Neoplasm
PMID 20368568 2010 Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer.
PMID 20847059 2010 Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation.
PMID 21455200 2011 Targeted therapies for thyroid tumors.
PMID 20065189 2010 Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.
PMID 22025146 2012 Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.
PMID 9681850 1998 Molecular biology of the MEN2 gene.
PMID 23056499 2012 Thyroid cancer cell lines harboring RET/PTC1 (TPC-1), RET M918T (MZ-CRC1) and RET C634W (TT) alterations, as well as TPC-1 xenografts, were treated with JAK inhibitor, AZD1480.
PMID 19255327 2009 Phase II trial of sorafenib in metastatic thyroid cancer.
PMID 21470995 2011 The effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cells.
PMID 18541894 2008 Phase II trial of sorafenib in advanced thyroid cancer.
PMID 23056499 2012 Thyroid cancer cell lines harboring RET/PTC1 (TPC-1), RET M918T (MZ-CRC1) and RET C634W (TT) alterations, as well as TPC-1 xenografts, were treated with JAK inhibitor, AZD1480.